Hepatocellular carcinoma (HCC) is one of the most common solid malignancies worldwide.
A large proportion of patients with HCC are diagnosed at advanced stages and are only …

Hepatocellular carcinoma (HCC) remains one of the most prevalent and deadliest cancers.
The poor outcome associated with HCC is dramatically changing due to the advent of …

Enhanced glycolysis and accumulation of lactate is a common feature in various types of
cancer. Intracellular lactate drives a recently described type of posttranslational modification …

Nonalcoholic fatty liver disease (NAFLD), including its more severe manifestation,
nonalcoholic steatohepatitis (NASH), has a global prevalence of 20–25% and is a major …

CRISPR-Cas9 gene editing has emerged as a powerful therapeutic technology, but the lack
of safe and efficient in vivo delivery systems, especially for tissue-specific vectors, limits its …

The liver is the sixth most common site of primary cancer in humans and the fourth leading
cause of cancer‐related death in the world. Hepatocellular carcinoma (HCC) accounts for …

Nonalcoholic fatty liver disease (NAFLD) is the leading chronic liver disease worldwide. Its
more advanced subtype, nonalcoholic steatohepatitis (NASH), connotes progressive liver …

Hepatocellular carcinoma (HCC) is one of the leading cancers worldwide. Classically, HCC
develops in genetically susceptible individuals who are exposed to risk factors, especially in …

Liver cancer is the fifth most common cancer and the second leading cause of malignant
death in Asia, and Asia reports 72.5% of the world's cases in 2020. As the most common …

Hepatocellular carcinoma (HCC)—the most common form of liver cancer—is an aggressive
malignancy with few effective treatment options. Lenvatinib is a small-molecule inhibitor of …